SUMMARY A limited clinical study was conducted to explore AIDS treatment by the Bio-frequency Spectrum Therapeutic Instrument (F.I.T. LAMP). F.I.T. LAMP has been shown to be safe and effective in the treatment for virus infections of herpes, influenza and hepatitis. Four cases of the treatment of AIDS patients by the MF LAMP are reported in this study. These AIDS patients showed CD4 positive cell counts decreased with time and mild infectious symptoms. After 15 treatments with MF LAMP in a period of 30 days, stability or increase in CD4 positive absolute cell count, percentage of CD4 positive cells and absolute lymphocyte count were observed in three subjects after the MF LAMP treatment. P24 antigen became undetectable in one of these three subjects. Elimination Of inflammatory Herpes lesions on the tongue and around the anus, and skin rash were evident in all cases. One subject who had 72 CD4 positive cell counts per cubic millimeter prior to the treatment showed decreased CD4 positive cell counts but showed negative hepatitis B virus surface antigen HBsAg) after being HBsAg positive for six years. This preliminary clinical study indicated that MF LAMP treatment might play an active role in improving immune function (T cell counts), eliminating mild infectious complications, especially eliminating ulcer, relieving pain, improving quality of personal life in HIV infected persons. The treatment showed no appreciable side effects at all. Encouraged by this very limited study expanded clinical trial with a Larger number trial is planned. INTRODUCTION More than 5 million people are infected with human immunodificiency virus HIV), the causative agent of the acquired immuno-deficiency syndrome (AIDS). HIV infection inevitably progresses to a fatal outcome. Progression of the disease, however, can be extremely variable [l]. Zidovudine (AZT) has shown to be effective in symptomatic and/or asymptomatic human HIV infection[2]. Hematologic abnormalities, myopathy and decreased in vitro and in vivo sensitivity of HIV to drug has been associated with extended AZT use[3-5]. Exploring safe, effective and cost-effective treatment for HIV infection remain important clinical objectives. The MF LAMP, originated by Chinese medical scientists, has shown significant effectiveness in improving immune function, reinforcing anti-inflammation, relieving pain, and enhancing tissue repairing and wound healing[6]. Significant clinical benefits of MF LAMP treatment on the virus infections of herpes. hepatitis and influenza have encouraged us to conduct this initial clinical trial of MF LAMP treatment for HIV . HIV infection progressively depleted CD4 positive helper/induce T lymphocytes(CD4 + cells) and creates an immune deficiency that accounts for the dramatically increased incidence of opportunistic infections and certain cancers in the AIDS patients[7]. In this study, we evaluated the effects of MF LAMP treatment on HIV infected subjects using HIV P24 level, CD4 + cell count, and mild infectious complications as markers. SUBJECT AND METHODS This study was designed us an initial clinical trial with no control group. Four patients from 35 to 50 years of age who where sero-positive for HIV antibody for 1-3 years, were enrolled. These patients exhibited enlarged lymph nodes at two or more sites, decreased absolute CD4 + cell counts, decreased percentage of CD4 + cells and the ratio of CD4/CD8. At entry, the subjects' neuro-psychiatric function was normal but severely depressed. Besides, subject 1 had fungus infection on his right foot; Subject 2 had Herpes Zoster lesion on his face and veneroid anal ulcer; Subject 3 had Hepatitis B virus (HBV) and Herpes Zoster virus (HZV) infection for 6 years with Herpes relapse about once about five weeks and veneroid anal ulcer (Fig. 1) while subject 4 had systemic skin rash, Hepatitis C virus infection and mild lung infection. All subjects received 15 MF LAMP treatments in a period of 30 days. Each treatment has a few 20 minutes therapy on the selected portions of the body(top head, chest, spinal cord and foot palms) and the inflammatory lesions. To evaluate the effects of the MF LAMP treatment, primary and secondary measures of efficacy were used. The primary efficacy criteria were based on changes of mild infectious complications. The secondary measures were based on HIV P24 antigen level and/or CD4+ cells as well us other hematological parameters. RESULTS Absolute CD4 + cell counts, percentage of CD4 + cells and absolute lymphocyte counts were stabilized or increased in three subjects, but decreased in CD4 + cell count in one subject. The ratio of CD4/CD8 was increased in two subjects and decreased in others. The value of P24 antigen become undetectable on the subject 1, the only one who had this measurement. The lymphadenopathy was completely gone in all subjects. during the MF LAMP treatment all subjects were experiencing a feeling of optimism and renewed strength. Fungus infection was completely eliminated in the case L At the end the clinical trial , the case 2 gained 206 CD4+ cells count, 71 CD20+ (Bl) cell count, 689 CD2+ (Tll), 300 CD8 + (T8), 405 CD3 + (D) cell count and 40 CD56(NKH) cell count per cubic millimeter; Herpes lesion and veneroid anal ulcer were completely gone. Such results have kept constant sixteen weeks after the termination of the treatment. After fifteen treatments the case 3 lost 56 CD4+ cells 211 CD8+ cells. However, his serum HBsAg testing became negative and his anal-lesion was completely gone(Fig.2) and had no Herpes relapse for eight weeks. The case 4 completely recovered from skin rash, mild lung infection and Herpes lesion, and showed an increase in CD4 + cells. However, his hepatitis C virus infection remained unchanged. The treatment had no effect on red blood cells; increases in hemoglobin was observed. DISCUSSION The present study indicated that the MF LAMP treatment plays an active role In normalizing immune function, eliminating certain inflammatory and infectious complications, relieving pain and suffering and improving personal life in HIV infected persons. In early 1994, Dr. Lin, zhou first proposed that Bio-spectrum of the human body might have positive effect in life of AIDS patients. The apparatus which can generate simulated Bio-spectrum of the human body was invented and applied to AIDS patients. Extensive studies of the MF LAMP treatment have been conducted and significant clinical benefits have been indicated in treating infectious diseases of hepatitis, herpes and influenza. It was hypothesized that the generated simulated MF LAMP can get into the body through resonance and body cells e.g. cells in immune system, nervous system, organs and tissue) can absorb this bio-energy to activate biochemical and physiological processes of all levels (electronic level. atomic level, molecular level and body fluids (blood and other level) to repairing and tissue to neurohumoral regulation, immune system, blood and other body fluids circulation are strengthened and improved for speed-up healing. The therapeutic effectiveness of the MF LAMP for viral diseases seems by strengthening immune system fighting against viruses. It is still too early to conclude the value of the MF LAMP therapy. Nevertheless, it indicates the advantages of not causing any side effects , being very simple to use, having low costs as well as being for overall well-being. Most important, it shows strong indication of clinic benefit in HIV infected Subjects, or at least improvement in the life quality of AIDS patients. REFERENCES 1. Mann, J. M., J. Acquir. Immune Syndr. 2. Friedland, G. H., New Engl. J. Med., 322 1000-1002, 1990 3. Richman, D. D., Sischl, . New Engl.J. Med. 317-, 192-197, 1987 4. Dournon, E, Matheron, W., et al., Lancet, 2, 1297-1302, 1988 6. Zhou L. et al., Abstr. 1st spectrum Medicine, Beijing, Nov. 12-17, 9-56, 1989 7. Bowen, D. L, Lane. H. C. Ann, Intern. Med., 103,704-709, 1985 8. Zhou L, Abstr. 1st National Biofrequency spectrum Medicine, Beijing, Nov. 12-17n 2-3n 1989 Acknowledgements: The Authors thank administrators, doctors, and staffs at The Health Education AIDS Liaison, New York for their assistance Note: This article is from the 17th Conference of National AIDS Research Foundation of China, Oct. 1997.